Business Context and Reporting Period
This Form 8-K, filed on August 15, 2025, by Neogen Corporation (NEOG), reports the grant of long-term incentive compensation to Named Executive Officers (NEOs) for fiscal year 2026. The filing details a strategic shift in compensation structure to better align executive pay with the company's transformational plan.
Key Financial Metrics and Compensation Details
The filing does not report operational financial metrics such as revenue, profit, cash flow, or debt. Instead, it discloses specific equity grant values and terms:
- CEO Grant Value: The total fiscal 2026 long-term incentive grant for CEO Mikhael Nassif is valued at $4.5 million.
- Stock Price: The closing price of common stock on the grant date was $5.43 per share.
- Performance Period: Three years (Fiscal Years 2026, 2027, and 2028).
Material Changes and Compensation Structure
Starting in fiscal year 2026, the company is altering its long-term incentive mix from stock options and restricted stock units (RSUs) to include Performance Share Units (PSUs). The new structure for NEOs consists of 50% PSUs and 50% stock options.
- PSU Metrics: Performance is measured by Revenue CAGR (40% weighting), Adjusted EBITDA Margin Expansion (30% weighting), and Cash Flow Conversion (30% weighting).
- Payout Range: Threshold performance yields 50% of target PSUs; maximum performance yields 200% of target PSUs.
- rTSR Modifier: A relative Total Shareholder Return modifier applies a 20% increase if performance is in the top 75th percentile of the peer group or a 20% decrease if below the 25th percentile.
- Specific Grants:
- Mikhael Nassif (CEO): 414,365 PSUs and options to purchase 1,065,042 shares.
- David Naemura (CFO/COO): 230,203 PSUs and options to purchase 591,690 shares.
- Amy Rocklin (CLCO): 119,705 PSUs and options to purchase 307,680 shares.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or outlook for the company's operations. Management commentary indicates that specific performance targets for the PSUs are confidential and omitted to prevent competitive harm. The CEO's stock options were granted as an inducement for his appointment effective August 11, 2025, and were not granted under the standard 2023 Omnibus Incentive Plan, though terms are materially consistent.
Investor Verification Checklist
- Verify the specific confidential performance targets for Revenue CAGR, Adjusted EBITDA Margin, and Cash Flow Conversion in future filings (e.g., Form 10-Q).
- Confirm the vesting schedule and exercise terms for the stock options granted to the CEO as an inducement grant versus the standard plan grants for other officers.
- Monitor the composition of the S&P 600 Healthcare Equipment & Services peer group used for the rTSR modifier.
- Review the actual award agreements filed as exhibits to the Form 10-Q for the quarter ending August 31, 2025, for full legal terms.